Showing 3471-3480 of 7106 results for "".
- IL-15 Blockade Plus Phototherapy Shows Promise in Vitiligohttps://practicaldermatology.com/news/il-15-blockade-plus-phototherapy-shows-promise-in-vitiligo/2486454/Targeting IL-15 with ordesekimab in combination with narrowband ultraviolet B (nbUVB) phototherapy led to greater repigmentation in patients with non-segmental vitiligo, according to results from a randomized, placebo-controlled trial presented by Brett King, MD, PhD, at the American Academy of D
- Study: Botanical Gummies Show Promise for Thinning Hairhttps://practicaldermatology.com/news/study-botanical-gummies-show-promise-thinning-hair/2468582/A recent 6-month study found that a daily gummy supplement with B vitamins, zinc, and botanicals improved hair density, strength, and perceived hair quality in women with thinning hair. Researchers for the double-blind, placebo-controlled trial included 65 healthy female participants aged
- Botox Approved for Platysma Bandshttps://practicaldermatology.com/news/botox-approved-platysma-bands/2468436/The US Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck (platysma bands) in adults, Allergan Aesthetics, an AbbVie company, announced. According to a press release, B
- Study: Fractional Laser and Botox Combo Shows Promise for Pore Reductionhttps://practicaldermatology.com/news/fractional-laser-and-botox-combination-shows-promise-pore-reduction/2462733/A single session of treatment with a fractional carbon dioxide laser followed by botulinum toxin type A was associated with significant reduction of facial pores in a pilot study presented at the American Society for Laser Medicine and Surgery (ASLMS) 43rd Annual Conference on Energy-b
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- ACR Study: Belimumab Improves CLE Toohttps://practicaldermatology.com/news/acr-study-belimumab-improves-cle/2461423/The B-cell inhibitor belimumab significantly improved cutaneous lupus erythematosus (CLE) whether or not patients also had systemic lupus erythematosus (SLE), according to research presented at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, Beli
- ASDS News: CellFX Clears Low-Risk Basal Cell Carcinoma Lesionshttps://practicaldermatology.com/news/asds-news-cellfx-clears-low-risk-basal-cell-carcinoma-lesions/2461374/CellFX procedure is effective for low-risk superficial and nodular basal cell carcinoma lesion clearance, according to research presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. "It is exciting and encouraging to see complete clearance of b
- Third Harmonic Bio Launches with an Eye on Chronic Urticariahttps://practicaldermatology.com/news/third-harmonic-bio-launches-with-an-eye-on-chronic-urticaria/2461078/Third Harmonic Bio is launching with the close of a Series B financing campaign. With total capital to date of $155 million, the company plans to fund development of its lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria. 
- Bimekizumab Bests Cosentyx in Achieving Complete Psoriasis Skin Clearancehttps://practicaldermatology.com/news/bimekizumab-bests-cosentyx-in-achieving-complete-psoriasis-skin-clearance/2460478/UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab outperformed the IL-17A inhibitor Cosentyx (secukinumab) in a head-to-head Phase 3 b study of adult patients with moderate-to-severe plaque psoriasis. This is the first head-to-head study comparing a
- Escalier Biosciences Closes Financing, Focuses on Psoriasishttps://practicaldermatology.com/news/escalier/2457821/Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topic